Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
- CONFIDENTIAL - 3 INTRODUCING EFRUXIFERMIN Efruxifermin (EFX) ē - FRUX ...
Schematic of efruxifermin structure. (adapted from ref.[1]) | Download ...
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 ...
2375240-92-7 | Efruxifermin | ChemScene
Safety and efficacy of once-weekly efruxifermin versus placebo in non ...
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH | New ...
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double ...
(PDF) Safety and efficacy of efruxifermin in metabolic dysfunction ...
Akero 宣布 Efruxifermin 获 FDA 突破性疗法认定用于 NASH_治疗_研究_脂肪
Pre-dose efruxifermin (EFX) concentrations over 16 weeks of dosing. EFX ...
Study on Efruxifermin for Patients with Compensated Cirrhosis Due to ...
Efruxifermin – Application in Therapy and Current Clinical Research
Efruxifermin Fast Tracked for Nonalcoholic Steatohepatitis ...
Efruxifermin Demonstrates Promising 96-Week Efficacy and Safety in ...
Safety and efficacy of once-weekly efruxifermin versus placebo in ...
Kombinasi Efruxifermin dan Agonis Reseptor GLP-1 untuk Steatohepatitis ...
Efruxifermin in non-alcoholic steatohepatitis - The Lancet ...
Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin
Efruxifermin (EFX) 治疗非酒精性脂肪性肝炎 (NASH)，FDA授予其“快速通道资格”-MedSci.cn
Akero Therapeutics | Efruxifermin for MASH | Clinical Trials
Efruxifermin Study - LiverRight: Virtual Liver Disease Clinic
Efruxifermin for NASH Clinical Trial 2024 | Power
Efruxifermin induces NASH resolution, improves fibrosis by at least 1 ...
Efruxifermin Demonstrates Potential in Treating Patients With MASH ...
Efruxifermin was associated with improvements in multiple non-invasive ...
Efruxifermin Shows Potential for Fibrosis Reduction in Phase 2b MASH ...
Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes
Breakthrough in MASH Treatment: Akero’s Efruxifermin Shines in Phase 2b ...
Akero Therapeutics | Efruxifermin for MASH | Pipeline
Efruxifermin in Compensated Cirrhosis due to NASH/MASH: Results from a ...
#VisualAbstract: Efruxifermin Did Not Reduce Liver Fibrosis in ...
Akero Therapeutics | Efruxifermin for MASH | Publications
Efruxifermin - Wikipedia
Efruxifermin Shows Long-Term Promise in MASH-Related Cirrhosis Despite ...
Efruxifermin for Compensated Liver Cirrhosis in MASH: Phase 2b Results ...
Efruxifermin Shows Durable Antifibrotic Benefit at 96 Weeks in MASH | AJMC
Efruxifermin Improves Fibrosis in Long-Term MASH Study - EMJ
Akero Therapeutics Advances MASH Treatment with Efruxifermin in Phase 3 ...
Updated Study Data Suggests Efruxifermin Benefits Stage 2 or 3 MASH ...
Efruxifermin reduces fibrosis in MASH cirrhosis | Multidisciplinary ...
S3-E54.2 - Presentation on Efruxifermin in NASH with Fibrosis - YouTube
poster on Tirzepatide and Efruxifermin for MASLD | GemPharmatech posted ...
Efruxifermin Combined with GLP-1RA Shows Clinical Efficacy in MASH ...
Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes | AJMC
A Global Disease, A Pioneering Treatment NASDAQ: AKRO
96周持续显著改善肝纤维化！MASH新药再获积极结果
Phase 3 Efuxifermin Fatty Liver/MASH Trial Ongoing; EASL 96 weeks ...
Akero Therapeutics | EFX for MASH | Fc-FGF21 Fusion Protein
里程碑！NASH新药不到半年就能起效，医药产业怎么看？|里程碑_新浪新闻
非酒精性脂肪性肝炎新药FGF21-Fc融合蛋白Efruxifermin：2期临床进一步证明其强大的降脂降纤维化疗效-MedSci.cn
A randomized, double-blind, placebo-controlled phase IIa trial of ...
EFX已获FDA的突破性疗法认认定，治疗非酒精性脂肪性肝炎|疗法|治疗|疾病|肿瘤|-健康界
FGF21 agonists: An emerging therapeutic for metabolic dysfunction ...
A novel GLP-1 and FGF21 dual agonist has therapeutic potential for ...
Frontiers | FGF21: An Emerging Therapeutic Target for Non-Alcoholic ...
Best-in-class潜力！每周1次皮下注射NASH新药获FDA突破性疗法认定 12月8日， Akero Therapeutics 公司 ...
Metabolic Dysfunction-Associated Steatohepatitis | Untapped potential ...
Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces body ...
Frontiers | A systematic review and meta-analysis of efruxifermin’s ...
Nat Med：Efruxifermin治疗非酒精性脂肪性肝炎的疗效和安全性分析-MedSci.cn
A systematic review and meta-analysis of efruxifermin’s efficacy in ...
肝臓病治療の新たな希望、Akero Therapeuticsのefruxiferminが示す顕著な改善効果
Efruxifermin: one step closer to disease-modifying therapy in fibrotic ...
Akero Therapeutics' Efruxifermin: A Beacon of Hope in Fatty Liver ...
Efruxifermin（EFX）治疗NASH：已获欧洲药品管理局的“优先药物称号”（PRIME）-MedSci.cn
(PDF) Efruxifermin, a long‐acting Fc‐fusion FGF21 analogue, reduces ...
GSRS
FDA授予efruxifermin快速通道资格，用于治疗非酒精性脂肪性肝炎（NASH）-上市-医保-临床适应症-香港济民药业
FGF21 Agonists: An Emerging Therapeutic for Metabolic Dysfunction ...
Efruxifermin(Efruxifermin) - 药物靶点：FGF21R_在研适应症：代偿期肝硬化，纤维化，非酒精性脂肪性肝炎_专利 ...
肝纤维化新疗法 | 突破性MASH疗法新药Efruxifermin公布耀眼临床数据 - 知乎
Efruxifermin|AKR-001|AMG876——药研档案
(PDF) Noncompetitive Immunoassay Optimized for Pharmacokinetic ...
00272-8/asset/4dd80eee-429b-4b8b-a921-fbabd7034077/main.assets/gr3b_lrg.jpg)
